nach oben

Erschienen in:

01.04.2023 | Case Report

Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome

verfasst von: Christopher N. Nguyen, Swaminathan P. Iyer, Madeleine Duvic, Prajak J. Barde, Ajit Nair, Kasi Viswanath Routhu, Auris O. Huen

Erschienen in: Investigational New Drugs | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Summary

Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common subtypes of cutaneous T cell lymphomas (CTCL). Advanced-stage MF/SS have poor prognoses and may be refractory to multiple systemic treatments. These cases can be difficult to achieve and maintain complete response and there is a need for novel therapeutics. Inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway by Tenalisib presents one such emerging drug. We report a relapsed/refractory SS patient achieving complete remission using the combination of Tenalisib and Romidepsin and subsequently maintaining long-duration CR with Tenalisib monotherapy.

Hristov AC, Tejasvi T, A Wilcox R (2021) Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 96(10):1313–1328. https://doi.org/10.1002/ajh.26299

Alpdogan O, Kartan S, Johnson W, Sokol K, Porcu P (2019) Systemic therapy of cutaneous T-cell lymphoma (CTCL). Chin Clin Oncol 8(1):10. https://doi.org/10.21037/cco.2019.01.02CrossRefPubMed

Lampson BL, Brown JR (2017) PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs 26(11):1267–1279. https://doi.org/10.1080/13543784.2017.1384815CrossRefPubMedPubMedCentral

Huen A, Haverkos BM, Zain J et al (2020) Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers (Basel) 12(8):2293. Published 2020 Aug 15. https://doi.org/10.3390/cancers12082293

Horwitz SM, Koch R, Porcu P et al (2018) Activity of the PI3K-δ, γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 131(8):888–898. https://doi.org/10.1182/blood-2017-08-802470CrossRefPubMedPubMedCentral

Safety and Efficacy of Tenalisib (RP6530) in Combination with Romidepsin in Patients with Relapsed/Refractory T-cell Lymphoma. Available online: https://clinicaltrials.gov/ct2/show/NCT03770000. Accessed 30 Apr 2022

Compassionate Use Study of Tenalisib (RP6530). Available online: https://clinicaltrials.gov/ct2/show/NCT03711604. Accessed 30 Apr 2022

Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M (2015) Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. Clin Lymphoma Myeloma Leuk 15(5):e83–e93. https://doi.org/10.1016/j.clml.2014.09.013CrossRefPubMed

Kim YH, Bagot M, Pinter-Brown L et al (2018) Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial [published correction appears in Lancet Oncol. 2018 Nov;19(11):e581]. Lancet Oncol 19(9):1192–1204. https://doi.org/10.1016/S1470-2045(18)30379-6

10.

Beygi S, Duran GE, Fernandez-Pol S, Rook AH, Kim YH, Khodadoust MS (2022) Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma [published online ahead of print, 2022 Apr 18]. Blood blood.2021014468. https://doi.org/10.1182/blood.2021014468

11.

Hughes CF, Khot A, McCormack C et al (2015) Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 125(1):71–81. https://doi.org/10.1182/blood-2014-07-588236CrossRefPubMed

12.

Talpur R, Thompson A, Gangar P, Duvic M (2014) Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk 14(4):297–304. https://doi.org/10.1016/j.clml.2014.01.010CrossRefPubMed

13.

Carlo-Stella C, Delarue R, Scarfo L et al (2020) A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study. Clin Lymphoma Myeloma Leuk 20(2):78–86. https://doi.org/10.1016/j.clml.2019.10.013CrossRefPubMed

14.

Iyer SP, Huen A, Ferreri AJM et al (2018) Pooled safety analysis and efficacy of Tenalisib (RP6530), a PI3K δ/γ inhibitor in patients with relapsed/refractory lymphoid malignancies. Blood 132:2925. https://doi.org/10.1182/blood-2018-99-112757CrossRef

15.

Iyer S, Huen A, Ai W et al (2021) Safety and efficacy of tenalisib given in combination with Romidepsin in patients with relapsed/refractory T-Cell Lymphoma: Final results from a phase I/II open label multi-center study. Blood (ASH Annual Meeting Abstracts)

16.

Kaneda MM, Messer KS, Ralainirina N et al (2016) PI3Kγ is a molecular switch that controls immune suppression. Nature 539(7629):437–442. https://doi.org/10.1038/nature19834

17.

Lewis J, Girardi M, Vakkalanka S, Viswanadha S, Bertoni F (2013) RP6530, a dual PI3Kδ/γ inhibitor, attenutates AKT phosphorylation and induces apoptosis in primary cutaneous T cell lymphoma (CTCL) cells. Blood 22:4418. https://doi.org/10.1182/blood.V122.21.4418.4418CrossRef

Titel: Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome
verfasst von: Christopher N. Nguyen
Swaminathan P. Iyer
Madeleine Duvic
Prajak J. Barde
Ajit Nair
Kasi Viswanath Routhu
Auris O. Huen
Publikationsdatum: 01.04.2023
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 2/2023
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-022-01315-6

Springer Medizin

Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome

Summary

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors

Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study

Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer

A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer

Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie